SIMPLE YET BRILLIANT

Developing an oral drug product is rarely straightforward. Many active pharmaceutical ingredients (APIs) exhibit poor aqueous solubility, limited permeability, or stability issues that can affect bioavailability and ultimately clinical performance. Addressing these challenges early in development is critical for reducing risk and avoiding delays later on. For companies without dedicated formulation teams or specialized equipment, working with an oral formulation CRO can provi

Veltio Pharma AB has recently been honored with the Bona Postulata-priset 2026, a recognition given to companies with strong growth potential. This award highlights the company’s commitment to improving pharmaceutical formulations through sustainable and practical technology. Being acknowledged alongside eight other remarkable companies based in Uppsala reflects the strength of Veltio Pharma’s vision and efforts in the pharmaceutical field. About the Bona Postulata-priset The

Drug development faces many challenges, but one of the most persistent is improving the solubility of active pharmaceutical ingredients. At BioStock 2025, a key Nordic forum connecting life science companies and investors, Veltio Pharma AB presented a promising solution to this problem. The company's CEO, Stina Lundgren, shared insights on how Veltio Pharma’s algae-derived porous cellulose offers a simple and effective alternative to traditional methods. Stina Lundgren, Velti

Veltio Pharma has taken an important step forward by joining the UIC Accelerate program at Uppsala Innovation Centre. This two-year accelerator will provide the company with tailored business coaching and strategic support to grow its nanotechnology-based oral formulation platform. This move aims to help Veltio Pharma bring more effective and sustainable therapies to the market. What UIC Accelerate Means for Veltio Pharma Being accepted into UIC Accelerate gives Veltio Pharma

Veltio Pharma has received recognition at Nordic Life Science Days 2025 by winning the Innovation Poster Prize. This award, chosen by event participants, highlights the company’s commitment to clear and effective communication of their ideas. The poster, titled “Simple yet brilliant,” captures the essence of our approach: innovation does not need to be complicated to be impactful. The Power of Simplicity in Innovation At many scientific and pharmaceutical events, complex data

Poorly soluble drugs pose a major challenge in pharmaceutical development. Many active pharmaceutical ingredients (APIs) struggle to dissolve effectively, limiting their absorption and therapeutic impact. A promising solution lies in a natural, renewable material: porous cellulose derived from green macroalgae. This approach offers a sustainable, efficient way to improve drug solubility and delivery. Why Poor Solubility Matters in Drug Delivery Many new drugs have low water s

Vitafoods Europe is a key event for the nutraceutical industry, where companies present new products and formulations that meet growing consumer demands for health, sustainability, and simplicity. At this year’s event, Veltio Pharma introduced a new concept tablet featuring AstaReal® Astaxanthin, a plant-based antioxidant known for its health benefits. This tablet combines clean-label ingredients with a proprietary porous algae-based cellulose, reflecting Veltio Pharma’s focu

Veltio Pharma AB recently closed a significant investment round, raising 8.5 million SEK. This capital injection marks a crucial step for the company. Expanding Research to Accelerate Drug Development With the new funding, Veltio Pharma plans to broaden its research activities. The investment will allow Veltio Pharma to: Increase the number of drug candidates under investigation Employ advanced technologies for formulation testing Collaborate with research institutions to v

Veltio Pharma has announced a significant leadership change with the appointment of Stina Lundgren as its new CEO. This move marks a new chapter for the company, promising fresh perspectives and renewed energy in its mission to advance pharmaceutical development. The decision reflects Veltio Pharma's commitment to growth and innovation in a competitive industry. Photo: Stina Lundgren. Who is Stina Lundgren? Stina Lundgren brings extensive experience in pharmaceutical leadersh